Summary
Several statements (e.g., abuse/dependence risk, amphetamine-related stimulant effects) are broadly consistent with label content, but the response does not meaningfully evaluate FDA label items such as indications, dosing, contraindications, warnings, interactions, or specific populations. Additionally, some assertions (e.g., “Schedule IV drugs generally have accepted medical uses” and controlled-substance pharmacy handling/documentation rules) are not supported by the provided FDA prescribing information excerpts.
Category Scores
Accurate Statements
Phentermine has potential for misuse or dependence.
Supported by Section 5.6 Risk of Abuse and Dependence (possibility of abuse should be kept in mind).
Phentermine is an amphetamine-like appetite suppressant.
Supported by Section 5.6 stating phentermine is related chemically and pharmacologically to amphetamine.
Phentermine has stimulant effects.
Partially supported by Section 5.6 (amphetamine-related) and Section 6 adverse reactions/central nervous system effects consistent with overstimulation.
Schedule IV drugs carry risk for dependence and misuse.
Not supported by the provided FDA prescribing information excerpts; only general controlled-substance knowledge is reflected here.
Phentermine prescribing and dispensing are subject to stricter rules than non-controlled medications.
Not supported by the provided FDA prescribing information excerpts.
Unsupported Statements
Phentermine is classified as a controlled substance in the United States.
Not addressed in the provided FDA label excerpts; FDA prescribing information excerpts supplied do not contain controlled-substance scheduling statements.
In the United States, phentermine is regulated as a Schedule IV medication under the Controlled Substances Act.
Not addressed in the provided FDA label excerpts.
Schedule IV drugs generally have accepted medical uses.
Not addressed in the provided FDA label excerpts.
Phentermine prescribing and dispensing are subject to stricter rules than non-controlled medications.
Not addressed in the provided FDA label excerpts.
Phentermine must be prescribed by a licensed clinician under controlled-substance requirements.
Not addressed in the provided FDA label excerpts.
Controlled-substance status is specific to each country’s drug scheduling rules.
Not addressed in the provided FDA label excerpts.
In the U.S., phentermine is Schedule IV, but rules can differ in other jurisdictions.
Not addressed in the provided FDA label excerpts.
Pharmacies handle controlled substances with additional documentation and dispensing controls compared with non-controlled drugs.
Not addressed in the provided FDA label excerpts.
Contradictions
Important Omissions
Indication details (short-term adjunct for exogenous obesity with specified BMI criteria) from Section 1.
Importance:
High
Dosage and administration instructions (e.g., individualized lowest effective dose, usual 37.5 mg daily timing, avoidance of late evening medication, pediatric limitation, renal maximum dose/avoidance) from Section 2.
Importance:
High
Contraindications list (including pregnancy contraindication, MAOI-within-14-days contraindication, hyperthyroidism, glaucoma, etc.) from Section 4.
Importance:
High
Key warnings/precautions beyond abuse potential, such as coadministration with other weight-loss drugs/serotonergic agents not recommended, PPH/valvular heart disease evaluation upon symptoms, tolerance/discontinuation, impairment of hazardous tasks, caution with hypertension, and diabetes medication adjustments.
Importance:
High
Drug interaction specifics (MAOIs contraindication; alcohol adverse reaction; insulin/oral hypoglycemic requirements may be altered; adrenergic neuron blocking drugs may have decreased hypotensive effect) from Section 7.
Importance:
High
Specific population instructions (pregnancy category X contraindication, nursing decision, pediatric not recommended, renal impairment limits/avoidance) from Section 8.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response includes some label-consistent safety themes (abuse/dependence and CNS overstimulation concepts) but omits multiple high-importance on-label safety requirements (contraindications, dosing, renal limits, pregnancy/nursing, interaction specifics, and key warnings). The uncontrolled-substance scheduling statements are also not supported by the provided FDA label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Many statements are about controlled-substance scheduling and dispensing rules that are not present in the supplied FDA prescribing information excerpts, while major on-label indication/dosing/contraindications/interactions/population safety information is omitted.
Suggested Improvement
Remove or clearly mark controlled-substance scheduling/dispensing-rule statements as outside the FDA label content; include and accurately cite the label-based indication (short-term adjunct with BMI criteria), dosing/administration, contraindications, warnings/precautions (including combination with other weight-loss drugs and serotonergic agents), interaction contraindications (MAOIs) and other interaction specifics, and key population constraints (pregnancy, nursing, pediatrics, renal impairment).